After the initial evaluation, the candidate genes were selected for further analysis, including DLBCL common (9 genes), proliferation (75 genes), stroma/EMT/TGF-β (34 genes), RAS (2 genes), MYC (8 genes), WNT (9 genes), hypoxia (4 genes), glycolysis (8 genes), angiogenesis (3 genes), gMDSC (15 genes), and mMDSC (80 genes). This evidence concerns the gene TGFB1 and diffuse large B-cell lymphoma.